JB Chemicals & Pharmaceuticals (506943) investor relations material

Executive summary

• Q2 FY26 revenue reached INR 1,085 crores, up 8% year-on-year, with net profit rising 19% to INR 208 crores and operating EBITDA up 12% to INR 319 crores.

• Domestic business outperformed the market, with all major brands delivering robust growth and recently acquired portfolios contributing positively.

• International business saw momentum return in the CDMO segment, supported by a strong order book for H2 FY26.

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved by the Board on November 11, 2025.

• Statutory auditors conducted a limited review and found no material misstatements in the financials.

Financial highlights

• Revenue grew 8% year-over-year to INR 1,085 crores in Q2 FY26; H1 FY26 revenue up 9% to INR 2,179 crores.

• Operating EBITDA increased 12% to INR 319 crores; margin improved to 29.4% from 28.4% year-over-year.

• Net profit rose 19% to INR 208 crores in Q2 FY26; H1 FY26 net profit up 17% to INR 410 crores.

• Gross margin improved by 200 basis points to 68.2%, and operating EBITDA margin increased by 100 basis points to 29.4% year-on-year.

• Operating cash flow for H1 FY26 was INR 363 crores; net cash and equivalents stood at INR 939 crores as of 30 September 2025.

Outlook and guidance

• Domestic business expected to maintain 12%-14% growth, driven by strong chronic segment performance.

• CDMO segment guidance reaffirmed at 12%-14% growth for the year, with a robust order book for H2 FY26.

• Gross margin guidance remains at 67%-69%, and EBITDA margin at 27%-29%.

• High single-digit growth expected in international formulations in H2 FY26.

• The company is undergoing a significant change in ownership and structure, with a planned amalgamation into Torrent Pharmaceuticals Limited, subject to statutory approvals.